drugset / Trial / NCT05283486
Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-06-07
- Completion
- 2023-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MYMD-1 | Unknown | 600 mg | Oral |
| Subject | MYMD-1 | Unknown | 750 mg | Oral |
| Subject | MYMD-1 | Unknown | 900 mg | Oral |
| Subject | MYMD-1 | Unknown | 1050 mg | Oral |